Related Experiment Video
Updated: Mar 17, 2026
DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
Gene regulation with carbon-based siRNA conjugates for cancer therapy
Lingmin Zhang1, Wenfu Zheng1, Rongbing Tang1
1CAS Key Lab for Biological Effects of Nanomaterials and Nanosafety, National Center for NanoScience and Technology, ZhongGuanCun BeiYiTiao, Beijing, 100190, China.
Abstract:
We report fluorescent carbon nanoparticle (FCN)-based small interfering RNA (siRNA) conjugates (C-siRNA) for gene regulation and cancer therapy. The C-siRNA has a core of chitosan-derived FCN and a shell of siRNA, and can down-regulate the expression of polo-like kinase-1 (Plk1), a master regulator of mitosis, via siRNA targeting Plk1 (siPlk1), for cancer therapy. The required amount of the FCNs is only ∼1/30 of that of the gold nanoparticles in delivering equal amount of siRNA. The C-siPlk1 led to ∼80% knockdown of cellular Plk1 mRNA in A375 cells, and induced apoptosis of the A375 cells (31.9%) and MCF-7 cells (20.33%), much higher than those by commercial nonviral gene delivery vectors, such as Lipofectamine 2000 in both cell lines (apoptosis rate < 10%). After the C-siPlk1 was administrated to A375 tumor-bearing mice intravenously, the tumor volume was less than 1/11 of the control groups. The C-siRNA can thus be powerful tools for gene delivery and gene therapy.
Insights
Fluorescent carbon nanoparticle (FCN)-based small interfering RNA (siRNA) conjugates effectively deliver gene therapy. These C-siRNA conjugates show promise for cancer treatment by down-regulating polo-like kinase-1 (Plk1) and reducing tumor growth.
Area of Science:
- Biotechnology
- Nanomedicine
- Cancer Therapy
Background:
- Gene regulation and cancer therapy are critical areas of research.
- Targeting polo-like kinase-1 (Plk1), a master regulator of mitosis, is a key strategy in cancer treatment.
- Efficient delivery of small interfering RNA (siRNA) is essential for gene silencing therapies.
Purpose of the Study:
- To develop and evaluate fluorescent carbon nanoparticle (FCN)-based siRNA conjugates (C-siRNA) for gene regulation and cancer therapy.
- To investigate the efficacy of C-siRNA in down-regulating Plk1 expression and inducing apoptosis in cancer cells.
- To assess the in vivo therapeutic potential of C-siRNA for tumor reduction.
Main Methods:
- Synthesized chitosan-derived FCNs as the core and conjugated siRNA targeting Plk1 (siPlk1) as the shell to form C-siPlk1.
- Quantified the amount of FCNs required for siRNA delivery compared to gold nanoparticles.
- Assessed Plk1 mRNA knockdown, cellular apoptosis rates in A375 and MCF-7 cells, and tumor volume in A375 tumor-bearing mice after intravenous administration of C-siPlk1.
Main Results:
- C-siRNA demonstrated efficient delivery of siRNA, requiring significantly less FCNs compared to gold nanoparticles.
- C-siPlk1 achieved approximately 80% knockdown of Plk1 mRNA in A375 cells.
- C-siPlk1 significantly induced apoptosis in A375 (31.9%) and MCF-7 (20.33%) cells, outperforming commercial vectors like Lipofectamine 2000.
- Intravenous administration of C-siPlk1 in A375 tumor-bearing mice resulted in tumor volume reduction to less than 1/11 of control groups.
Conclusions:
- Fluorescent carbon nanoparticle (FCN)-based siRNA conjugates (C-siRNA) are effective tools for gene delivery and gene therapy.
- C-siRNA exhibits potent anti-cancer activity through Plk1 down-regulation and induction of apoptosis.
- C-siRNA holds significant promise for developing novel cancer therapeutics with enhanced efficacy and reduced material requirements.
More Related Videos
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
09:18TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
Published on: June 2, 2016
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22MicroRNAs
01:22MicroRNAs
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...